TX Houston의 여포성 림프종 임상 시험
여포성 림프종 관련 연구 20개가 Houston 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
피험자 모집 중2/3상
- University of Texas-MD Anderson Cancer Center ( Site 1323), Houston
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
피험자 모집 중3상
- Center for Oncology and Blood Disorders, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
피험자 모집 중1상
- MD Anderson Cancer Center, Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
피험자 모집 중1상
- Baylor College of Medicine, Houston
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
피험자 모집 중3상
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
피험자 모집 중관찰 연구
- Texas Children's Hospital, Houston
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
피험자 모집 중1/2상
- The University of Texas MD Anderson Cancer Center, Houston
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
피험자 모집 중2상
- M D Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
피험자 모집 중1/2상
- University of Texas MD Anderson Cancer Center, Houston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
피험자 모집 중3상
- MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
피험자 모집 중1상
- The University of TX MD Anderson Cancer Center, Houston
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
피험자 모집 중2상
- Research Site, Houston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
피험자 모집 중1/2상
- Md Anderson Cancer Center, Houston
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
피험자 모집 중1/2상
- Research Site, Houston
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
피험자 모집 중2상
- MD Anderson Cancer Center, Houston
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
피험자 모집 중2상
- Memorial Hermann Hospital / UTHealth McGovern Medical School at Houston, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
피험자 모집 중1상
- MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
피험자 모집 중1상
- MD Anderson Cancer Center, Houston
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
피험자 모집 중1상
- Oncology Consultants, Houston
- University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
피험자 모집 중관찰 연구
- Massive Bio SYNERGY-AI site, Houston
다른 도시의 여포성 림프종 시험
- New York City, NY연구 24개
- Milwaukee, WI연구 19개
- Nashville, TN연구 18개
- Baldwin Park, CA연구 16개
- Seattle, WA연구 16개
- Boston, MA연구 16개
- Durham, NC연구 16개
- Salt Lake City, UT연구 13개
- Columbus, OH연구 13개
- Los Angeles, CA연구 13개
- Chicago, IL연구 12개
- San Antonio, TX연구 12개
Houston의 다른 연구
- 비소세포폐암연구 143개
- 유방암연구 126개
- 암 (전체)연구 124개
- 대장직장암연구 101개
- 전이성 암연구 100개
- 난소암연구 90개
- 급성 골수성 백혈병연구 88개
- 폐암연구 78개
- 전립선암연구 73개
- 자궁내막암연구 69개
- 흑색종연구 61개
- 췌장암연구 59개
ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.